What is the validity period for Netherlands marketing authorisations?

Marketing authorisations for the Dutch market are valid for five years. After five years, the Medicines Evaluation Board (MEB) evaluates whether the authorisation should be renewed. Renewal applications must demonstrate that the product continues to have a positive benefit-risk balance based on updated safety and efficacy data collected during the five-year period.

What is the MEB-ZIN Parallel Procedure and how does it reduce market access time?

The MEB-ZIN Parallel Procedure pilot allows reimbursement assessment by Zorginstituut Nederland (ZIN) to begin at day 180 of the EMA centralised procedure, which is 30 days earlier than the standard day-210 start. This earlier evaluation can reduce total market access time by approximately 90 days on average. Final reimbursement approval is granted after the European Commission issues the marketing authorisation.

When is a pharmacoeconomic assessment required for GVS reimbursement?

Zorginstituut Nederland conducts pharmacoeconomic assessment of outpatient medicines when, within the first three years after market introduction, the total annual cost is EUR 10 million or more, or when total annual costs are between EUR 1 million and EUR 10 million and the per-patient cost per year is EUR 50,000 or more. In such cases, the marketing authorisation holder must submit a pharmacoeconomic evaluation, pharmacotherapeutic dossier, and budget impact analysis.

What are post-approval regulatory requirements in the Netherlands?

After approval, companies must manage regulatory lifecycle obligations such as variation submissions, marketing authorisation renewals, pharmacovigilance compliance, safety reporting, and labelling updates in accordance with European Union and Dutch regulatory requirements.

Regulatory Services in Netherlands

Regulatory Affairs Services Provider in Netherlands

DDReg provides regulatory affairs services in Netherlands for pharmaceutical companies. Our team manages MEB marketing authorisations via national, MRP, and DCP procedures, coordinates ZIN reimbursement applications including GVS and Annex 1B submissions, participates in the MEB-ZIN Parallel Procedure pilot, and delivers regulatory outsourcing Netherlands mandates from dossier preparation through lifecycle management.

Netherlands Regulatory Framework

The Medicines Evaluation Board (MEB; College ter Beoordeling van Geneesmiddelen or CBG) is the Dutch national competent authority for pharmaceuticals. MEB issues marketing authorisations for the Netherlands market via national procedure, serves as reference or concerned member state in MRP and DCP, and assesses variations and renewals. Marketing authorisations are valid for five years; after five years, MEB considers renewal. The Dutch Medicines Act governs pharmaceutical regulation.

The National Health Care Institute (ZIN; Zorginstituut Nederland) advises the Minister for Medical Care and Sport on whether medicines are eligible for the Medicine Reimbursements Scheme (GVS). ZIN assesses therapeutic substitutability, added therapeutic value, and cost-effectiveness. The MEB-ZIN Parallel Procedure pilot launched in April 2019 allows ZIN reimbursement assessment to begin at day 180 of EMA centralised procedure, reducing market access time by approximately 90 days. Medicinal products must comply with maximum prices under the Maximum Prices for Medicines Regulation (Wgp).

Marketing Authorisation Services - MEB Procedures

+ MEB National Procedure
- National Dossier Preparation: Preparation of CTD Module 1 with Dutch-specific requirements, eCTD submission, product characteristics, package leaflet and labelling text in line with MEB requirements, including braille text on packaging.
- MEB Assessment Coordination: Standard 210-day assessment timeline management including responses to Day 120 and Day 180 questions, Dutch-language correspondence handling, and coordination of assessor queries.
- MEB Scientific Advice: Pre-submission regulatory advice on registration requirements, including the possibility of combined MEB–ZIN scientific advice covering both registration and reimbursement considerations.
- Simplified Procedure: Applicable for products with dossiers identical to previously authorised products, including generic and hybrid applications.
+ MRP and DCP Procedures
- Netherlands as RMS: National procedure forms Day 0 for Mutual Recognition Procedure, with MEB acting as Reference Member State and coordinating recognition by Concerned Member States.
- Netherlands as CMS: Participation in MRP and Decentralised Procedure recognition processes, including Day 90 milestones and adaptation of Dutch CTD Module 1 based on RMS assessment.
- Article 29 Referrals: Coordination by MEB where the Netherlands is involved in referral procedures arising from MRP/DCP disagreements.
+ Lifecycle Management
- Variations: Submission and management of Type IA, IB, and Type II variations in accordance with EU variation regulations, including MEB timelines and worksharing procedures.
- Renewals: Preparation and submission of five-year renewal applications supported by consolidated assessment reports and ongoing demonstration of product safety and efficacy.
- Transfer of MA: Management of marketing authorisation holder transfer procedures and required MEB notifications.

Pricing and Reimbursement - ZIN and GVS

+ GVS Reimbursement Applications
- Therapeutic Substitutability Assessment: Medicinal products considered therapeutically substitutable are included in a GVS cluster following evaluation by the ZIN Scientific Advisory Board, with reference pricing applied within the cluster.
- Annex 1B Applications: Non-substitutable products demonstrating added therapeutic value and cost-effectiveness may be proposed for full reimbursement, subject to Ministerial decision and listing in Annex 1B of the Rzv.
- Pharmacoeconomic Dossier: Full pharmacoeconomic assessment required where total expected costs exceed EUR 10 million annually during the first three years, or where costs are EUR 1–10 million with expenditure of EUR 50,000 or more per patient per year. Includes budget impact analysis and pharmacotherapeutic evaluation.
- ZIN Procedure Timeline: Statutory 90-day assessment timeline in accordance with Directive 89/105/EEC, including consultation with health insurers, healthcare professionals, and patient organisations, followed by final advice from the ZIN Executive Board to the Minister.
+ MEB-ZIN Parallel Procedure Pilot
- Accelerated Market Access: ZIN reimbursement assessment may begin at Day 180 of the EMA centralised procedure, approximately 30 days earlier than the standard approach, potentially saving around 90 days. Final reimbursement decisions are issued after European Commission marketing authorisation.
- Eligibility Criteria: Applicable where Annex 1B placement is requested or where inclusion is expected in the Sluis procedure. Requires proactive company participation and engagement in pilot consultation meetings.
- Combined MEB-ZIN Advice: Joint scientific advice addressing both marketing authorisation requirements (MEB) and reimbursement evidence expectations (ZIN), particularly relevant for Phase III clinical development strategy and study design.

Netherlands Registration Timelines

Procedure	Standard Timeline	Authority
National	210 days	MEB
MRP (Netherlands RMS)	National + 90 days	MEB as RMS
MRP/DCP (Netherlands CMS)	90 days from Day 0	MEB as CMS
Type IA variation	30 days	MEB
Type IB variation	30 days	MEB
Type II variation	60–90 days	MEB
Renewal	90 days	MEB
ZIN GVS assessment	90 days (statutory)	ZIN advice to Minister
MEB-ZIN Parallel (pilot)	Begins Day 180 of EMA procedure	MEB + ZIN coordinated

DDReg Netherlands Expertise

MEB eCTD and Dutch Module 1 Requirements

eCTD Submission Standards: MEB requires submissions in eCTD format aligned with the European CTD structure, including Dutch-specific Module 1 content.
Patient Information Requirements: Package leaflets must be written in plain language for end-users.
Labelling Compliance: Product labelling must include braille text on packaging.
Regulatory Coordination Support: Preparation of Dutch Module 1 documentation, coordination of labelling and package leaflets, and eCTD technical validation management.

ZIN Pharmacoeconomic Assessment Navigation

FE Threshold Requirements: A full pharmacoeconomic assessment is required where total expected costs exceed EUR 10M annually, or EUR 1–10M with EUR 50K+ per patient per year.
Pharmacoeconomic Dossier Preparation: Preparation aligned with ZIN Scientific Advisory Board standards including budget impact analysis.
Therapeutic Value Demonstration: Support for Annex 1B reimbursement applications.

MEB-ZIN Parallel Procedure Coordination

Accelerated Market Access: Parallel procedure pilot enables ~90-day faster access for innovative medicines.
Eligibility and Application Management: Coordination of eligibility submissions and initiation of ZIN assessment at Day 180 of EMA procedure.
Pilot Procedure Support: Consultation meetings, evaluation milestones, and authority coordination.

Global Reach Explorer

Find Your Solution

Progress0 / 3 selected

Our Regulatory Affairs Consulting Services in Netherlands portfolio covers:

Regulatory Strategies

The pharmaceutical industry operates under stringent regulations to ensure the safety, efficacy, and quality...

New Product Marketing Authorizations

Navigating marketing authorization is a complex and time-sensitive process. Every country has its own regulatory framework...

Gap Analysis and Remediation

In the highly regulated pharmaceutical industry, maintaining compliance is critical. Regulatory gap analysis helps identify deficiencies in technical documentation...

Regulatory Due Diligence

Regulatory issues arise unexpectedly and can create significant strain on a company’s resources. As such, it is advisable for all companies to carry out regular and frequent regulatory due diligence and audits...

API & DMF services

Drug Master Files (DMFs) contain confidential and detailed information regarding API processes—from manufacturing to storage. DDReg’s DMF Services deliver precise...

CMC Advisory

DDReg’s CMC services are dedicated to assisting customers in developing robust and an efficient regulatory strategy through all development phases - authoring...

Post Approval Life Cycle Management

Maximize product value with expert pharma lifecycle management. Our dedicated team ensures that your product remains on shelves and compliant with ever-evolving regulations through strategic post-approval management...

Certification Services

Partner with DDReg to navigate the complex process of regulatory certification of pharmaceutical...

ANDA and MA Holder Services

Our comprehensive services support both Abbreviated New Drug Applications (ANDA) and Marketing Authorization processes.

Publishing & Submission

Our comprehensive digital solution transforms traditional paper dossier submissions into a streamlined electronic format. With robust infrastructure and cutting‐edge management processes...

Labeling

With experts experienced in Consumer Health Care (CHC) products, we offer updated labeling and compliance packages that assist in the development of product labeling, artwork review & compliance, and claim substantiation.

Contact DDReg for Regulatory Affairs Services in Netherlands

Frequently Asked
Questions

Get in Touch

Send a Mail

bd@ddregpharma.com

Make a Call

+91 9650803491

Our Headquarter

Gurgaon, India